Cargando…

Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population

INTRODUCTION: Approximately 30% of patients with a first acute pericarditis episode experience a recurrence ≤ 18 months; ~ 15% experience multiple recurrences. This study assessed the recurrence and economic burden among patients with multiple recurrences. METHODS: Adults with idiopathic pericarditi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, David, Laliberté, François, Majeski, Christine, Magestro, Matt, Lejeune, Dominique, Duh, Mei Sheng, Lim-Watson, Michelle, Paolini, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478772/ https://www.ncbi.nlm.nih.gov/pubmed/34417724 http://dx.doi.org/10.1007/s12325-021-01868-7

Ejemplares similares

US Database Study of Clinical Burden and Unmet Need in Recurrent Pericarditis
por: Klein, Allan, et al.
Publicado: (2021)

Clinical Burden and Unmet Need in Recurrent Pericarditis: A Systematic Literature Review
por: Klein, Allan, et al.
Publicado: (2020)

Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States
por: Bogart, Michael, et al.
Publicado: (2023)

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
por: Lin, David, et al.
Publicado: (2021)

Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
por: Brucato, Antonio, et al.
Publicado: (2022)

Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
por: Zhdanava, Maryia, et al.
Publicado: (2020)

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
por: Khorana, Alok A., et al.
Publicado: (2018)

A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States
por: Zhang, Wenjie, et al.
Publicado: (2018)

Economic Burden of Anemia in an Insured Population
por: Nissenson, Allen R., et al.
Publicado: (2005)

Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population
por: Law, Amy, et al.
Publicado: (2016)

Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
por: Kabadi, Shaum M., et al.
Publicado: (2019)

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA
por: Chu, David S, et al.
Publicado: (2013)

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population
por: Bogart, Michael, et al.
Publicado: (2019)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Idiopathic Recurrent Pericarditis: Not Really So Idiopathic?
por: Roubille, François, et al.
Publicado: (2022)

Economic burden of paediatric-onset disabilities among young and middle-aged adults in the USA: a cohort study of privately insured beneficiaries
por: Whitney, Daniel, et al.
Publicado: (2019)

The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States
por: Saxena, Kunal, et al.
Publicado: (2023)

Recurrent Pericarditis in Children and Adolescents
por: Tombetti, Enrico, et al.
Publicado: (2019)

Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
por: Brucato, Antonio, et al.
Publicado: (2023)

Financial burden imposed on the insured patients for private treatment: Evidence from a state of Iran
por: Etemadi, Manal, et al.
Publicado: (2019)

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market
por: Shih, Ya-Chen Tina, et al.
Publicado: (2021)

New Proposal of Private Insurance Program for Dementia Patients: Design of Sustainable Private Insurance Program in Korea
por: Park, Kun-Woo, et al.
Publicado: (2017)

Recurrent pericarditis in an adolescent with Crohn's colitis
por: Das, Bibhuti B, et al.
Publicado: (2020)

Recurrent pericarditis: an update on diagnosis and management
por: Andreis, Alessandro, et al.
Publicado: (2021)

Management of Recurrent Pregnancy-Related Pericarditis
por: Ibrahim, Michel, et al.
Publicado: (2022)

Recurrent pericarditis after Covid-19()
por: Rodrigo Domínguez, David, et al.
Publicado: (2022)

Government regulation of private health insurance
por: Motaze, Nkengafac V, et al.
Publicado: (2015)

Private dental insurance expenditure in Brazil
por: Cascaes, Andreia Morales, et al.
Publicado: (2018)

Government regulation of private health insurance
por: Motaze, Nkengafac Villyen, et al.
Publicado: (2021)

The Impact of Health Insurance on Economic Burden for Hepatitis B Inpatients in China
por: ZHANG, Hua, et al.
Publicado: (2016)

Economic Burden of HIV in a Commercially Insured Population in the United States
por: Chen, Cindy Y., et al.
Publicado: (2023)

Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States
por: Yu, Tzy-Chyi, et al.
Publicado: (2019)

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
por: Shore, Neal D., et al.
Publicado: (2021)

Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
por: Klein, Allan L, et al.
Publicado: (2021)

Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
por: Mostaghimi, Arash, et al.
Publicado: (2022)

Acute Recurrent Pericarditis Accompanied by Graves' Disease
por: Koo, Eun Hee, et al.
Publicado: (2012)

Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis
por: Abadie, Bryan Q., et al.
Publicado: (2022)

Economic burden of asthma among patients visiting a private hospital in South India
por: Aneeshkumar, Surendran, et al.
Publicado: (2018)

Changing Nature of Public and Private Health Insurance
por: Goody, Brigid, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_chc3jck7tvmer0rhp5tdfalat5